BeStock  

Bioventus BVS

US equityMarket cap rank #3338Medical Devices
$12.77 −$0.33 (-2.52%)
Pre-market · Oct 8, 7:20 am ET · After hours $12.77 0.00%
Open$13.00
Prev close$13.10
Day range$12.75 – $13.36
Volume365.2K
Market cap$872.26M
P/E (TTM)16.4
Dividend yield–

Price chart

Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.

Technical signals

Trend readLeaning bearish

2 bullish · 5 bearish of 7 signals

IndicatorValueSignalReading
Price vs 20-day average-4.2%BearishTrading below the 20-day average of $13.32
Price vs 50-day average-6.8%BearishTrading below the 50-day average of $13.70
Price vs 200-day average+23.3%BullishTrading above the 200-day average of $10.36
50-day vs 200-day50d above 200dBullishThe 50-day average is above the 200-day average
RSI (14)40.8BearishMomentum leans negative
MACD (12,26,9)-0.08BearishMACD line is below its signal line
Bollinger band position15%BearishInside the 20-day bands

Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.

Levels & volatility

Moving averages

AverageLevelPrice vs. it
20-day SMA$13.32-4.2%
50-day SMA$13.70-6.8%
200-day SMA$10.36+23.3%

Recent price levels

LevelPrice
20-day high$14.15
20-day low$12.34
60-day high$15.89
60-day low$11.35
Upper Bollinger band$14.11
Lower Bollinger band$12.54

The 50-day average is currently 32.2% above the 200-day average — consistent with a “golden cross” (bullish) configuration.

30-day volatility35.7%
Average true range3.80% of price
Max drawdown (1y)-27.5%
Volume (10d vs 90d)0.63x

Discussion

No comments yet — be the first to weigh in on BVS.

Leave a comment

Scroll to Top